News | May 21, 2026
Eris Lifesciences reports Q4 FY26 revenue of Rs. 757 crore; PAT jumps 173%
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
Solutions designed to help clinicians reduce administrative burden, improve diagnostic accuracy, and spend more time with patients
Dr. Upadhyay brings over 25 years of global leadership experience across life sciences, regulated manufacturing, diagnostics, and research-led environments
She brings extensive expertise in managing global and domestic procurement operations
The company’s revenue stood at Rs. 287.68 crore, reflecting a 4.7 percent increase over Rs. 274.71 crore reported in FY25
Company’s FY26 EBITDA rses 20% to Rs. 8,475 crore; Net profit grows 15% amid strong operational performance
By leveraging digital screening and remote consultation, the medical community is moving beyond the confines of the clinic
A high-resolution CT scan with 0.5 mm slices was used to design a customised titanium implant tailored to the patient’s anatomy and bone loss pattern
In his new role, he will lead the growth strategy for the group’s operations, including Apothecon Pharmaceuticals in India and Navinta LLC in the United States
The product has received tentative USFDA approval, Health Canada notice of compliance, and Indian regulatory approval
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
